Connection
Brian Kavanagh to Radiotherapy Dosage
This is a "connection" page, showing publications Brian Kavanagh has written about Radiotherapy Dosage.
|
|
Connection Strength |
|
 |
|
 |
|
2.036 |
|
|
|
-
Kavanagh BD, Ding M, Schefter TE, Stuhr K, Newman FA. The dosimetric effect of inhomogeneity correction in dynamic conformal arc stereotactic body radiation therapy for lung tumors. J Appl Clin Med Phys. 2006 May 25; 7(2):58-63.
Score: 0.256
-
Kavanagh BD, Timmerman RD, Benedict SH, Wu Q, Schefter TE, Stuhr K, McCourt S, Newman F, Cardinale RM, Gaspar LF. How should we describe the radioblologic effect of extracranial stereotactic radlosurgery: equivalent uniform dose or tumor control probability? Med Phys. 2003 Mar; 30(3):321-4.
Score: 0.205
-
Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base. Urol Oncol. 2016 Apr; 34(4):165.e1-9.
Score: 0.124
-
Amini A, Jones BL, Yeh N, Rusthoven CG, Armstrong H, Kavanagh BD. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base. Int J Radiat Oncol Biol Phys. 2015 Dec 01; 93(5):1052-63.
Score: 0.122
-
Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, Miften M. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3 Suppl):S101-7.
Score: 0.083
-
McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):112-8.
Score: 0.075
-
Kavanagh BD, Kelly K, Kane M. The promise of stereotactic body radiation therapy in a new era of oncology. Front Radiat Ther Oncol. 2007; 40:340-351.
Score: 0.067
-
Kavanagh BD, McGarry RC, Timmerman RD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol. 2006 Apr; 16(2):77-84.
Score: 0.063
-
Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar LE. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006; 45(7):848-55.
Score: 0.062
-
Bayat F, Miller B, Park Y, Yu Z, Alexeev T, Thomas D, Stuhr K, Kavanagh B, Miften M, Altunbas C. 2D antiscatter grid and scatter sampling based CBCT method for online dose calculations during CBCT guided radiation therapy of pelvis. Med Phys. 2024 Apr; 51(4):3053-3066.
Score: 0.054
-
Kavanagh BD. The emperor's new isodose curves. Med Phys. 2003 Sep; 30(9):2559-60.
Score: 0.053
-
Kavanagh BD, Schefter TE, Wu Q, Tong S, Newman F, Arnfield M, Benedict SH, McCourt S, Mohan R. Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. Semin Radiat Oncol. 2002 Jul; 12(3):260-71.
Score: 0.049
-
Kavanagh BD, Segreti EM, Koo D, Amir C, Arthur D, Wheelock J, Cardinale RM, Schmidt-Ullrich RK. Long-term local control and survival after concomitant boost accelerated radiotherapy for locally advanced cervix cancer. Am J Clin Oncol. 2001 Apr; 24(2):113-9.
Score: 0.045
-
Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Shaw EG, Pearlman AD, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys. 2001 Mar 15; 49(4):1133-9.
Score: 0.045
-
Cardinale RM, Kavanagh BD. Conformal radiotherapy: what is it and why does it matter? Surg Oncol Clin N Am. 2000 Jul; 9(3):415-34, vii.
Score: 0.043
-
Kavanagh BD, Zwicker RD, Segreti EM, Lindquist LA, Fulcher AS, Hundley GM, Spindler JA, Cardinale RM. Gynecologic brachytherapy: digital fluoroscopy for placement verification and treatment planning. Radiology. 2000 Jun; 215(3):900-3.
Score: 0.042
-
Vinogradskiy Y, Rusthoven CG, Schubert L, Jones B, Faught A, Castillo R, Castillo E, Gaspar LE, Kwak J, Waxweiler T, Dougherty M, Gao D, Stevens C, Miften M, Kavanagh B, Guerrero T, Grills I. Interim Analysis of a Two-Institution, Prospective Clinical Trial of 4DCT-Ventilation-based Functional Avoidance Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1357-1365.
Score: 0.038
-
Kavanagh BD, Gieschen HL, Schmidt-Ullrich RK, Arthur D, Zwicker R, Kaufman N, Goplerud DR, Segreti EM, West RJ. A pilot study of concomitant boost accelerated superfractionated radiotherapy for stage III cancer of the uterine cervix. Int J Radiat Oncol Biol Phys. 1997 Jun 01; 38(3):561-8.
Score: 0.034
-
Jackson MW, Palma DA, Camidge DR, Jones BL, Robin TP, Sher DJ, Koshy M, Kavanagh BD, Gaspar LE, Rusthoven CG. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma. J Thorac Oncol. 2017 04; 12(4):734-744.
Score: 0.034
-
Vinogradskiy Y, Schubert L, Diot Q, Waxweiller T, Koo P, Castillo R, Castillo E, Guerrero T, Rusthoven C, Gaspar L, Kavanagh B, Miften M. Regional Lung Function Profiles of Stage I and III Lung Cancer Patients: An Evaluation for Functional Avoidance Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1273-80.
Score: 0.032
-
Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, Raben D, Cooley S, Brindle J, Xie XJ, Pistenmaa D, Timmerman R. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):e43-e49.
Score: 0.032
-
Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DWN, Pistenmaa D, Lotan Y, Timmerman R. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016 05; 59:142-151.
Score: 0.032
-
Zhao J, Yorke ED, Li L, Kavanagh BD, Li XA, Das S, Miften M, Rimner A, Campbell J, Xue J, Jackson A, Grimm J, Milano MT, Spring Kong FM. Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. Int J Radiat Oncol Biol Phys. 2016 Aug 01; 95(5):1357-1366.
Score: 0.032
-
Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base. J Urol. 2016 May; 195(5):1453-1458.
Score: 0.031
-
Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):509-17.
Score: 0.028
-
Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, Camidge DR. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):892-8.
Score: 0.027
-
Kavanagh BD, Brizel DM, Leopold KA, Acker JC. Radiation therapy for head and neck cancer in a patient with Takayasu's arteritis. Acta Oncol. 1994; 33(1):73-4.
Score: 0.027
-
Howells CC, Stinauer MA, Diot Q, Westerly DC, Schefter TE, Kavanagh BD, Miften M. Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):e441-6.
Score: 0.024
-
H?yer M, Swaminath A, Bydder S, Lock M, M?ndez Romero A, Kavanagh B, Goodman KA, Okunieff P, Dawson LA. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):1047-57.
Score: 0.024
-
Diot Q, Kavanagh B, Timmerman R, Miften M. Biological-based optimization and volumetric modulated arc therapy delivery for stereotactic body radiation therapy. Med Phys. 2012 Jan; 39(1):237-45.
Score: 0.024
-
Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011 Sep 01; 117(17):4060-9.
Score: 0.022
-
Fields EC, Damek D, Gaspar LE, Liu AK, Kavanagh BD, Waziri A, Lillehei K, Chen C. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):51-7.
Score: 0.022
-
Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Gaspar LE, Lillehei K, Waziri A, Damek DM, Chen C. Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):211-7.
Score: 0.021
-
Diot Q, Olsen C, Kavanagh B, Raben D, Miften M. Impact of anatomical interventions on the localization of post-prostatectomy cancer patients. Med Phys. 2010 Feb; 37(2):629-37.
Score: 0.021
-
Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter TE, Kavanagh BD, Larner JM. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):796-801.
Score: 0.020
-
Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. 2009; 48(4):578-83.
Score: 0.019
-
Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter TE. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol. 2008 Jun; 31(3):264-70.
Score: 0.018
-
Ballonoff A, Rusthoven KE, Schwer A, McCammon R, Kavanagh B, Bassetti M, Newman F, Rabinovitch R. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1465-71.
Score: 0.018
-
Timmerman R, Abdulrahman R, Kavanagh BD, Meyer JL. Lung cancer: a model for implementing stereotactic body radiation therapy into practice. Front Radiat Ther Oncol. 2007; 40:368-385.
Score: 0.017
-
Baisden JM, Reish AG, Sheng K, Larner JM, Kavanagh BD, Read PW. Dose as a function of liver volume and planning target volume in helical tomotherapy, intensity-modulated radiation therapy-based stereotactic body radiation therapy for hepatic metastasis. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):620-5.
Score: 0.016
-
Cardinale RM, Wu Q, Benedict SH, Kavanagh BD, Bump E, Mohan R. Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1999 Sep 01; 45(2):515-20.
Score: 0.010
-
Zwicker RD, Arthur DW, Kavanagh BD, Mohan R, Schmidt-Ullrich RK. Optimization of planar high-dose-rate implants. Int J Radiat Oncol Biol Phys. 1999 Jul 15; 44(5):1171-7.
Score: 0.010
-
Zwicker RD, Atari NA, Kavanagh BD, Gieschen HL, Arnfield MR, Khandelwal SR, Schmidt-Ullrich RK. Clinical use of a digital simulator for rapid setup verification in high dose rate brachytherapy. Int J Radiat Oncol Biol Phys. 1995 Nov 01; 33(4):931-6.
Score: 0.008
-
Arthur D, Kaufman N, Schmidt-Ullrich R, Kavanagh B, Simpson P, Hill M, Ali M. Heuristically derived tumor burden score as a prognostic factor for stage IIIB carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4):743-51.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|